EIKN

MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center. Dr. Timothy A. Yap currently serves as Vice President and Head of Clinical Development in

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)

10-Q - Eikon Therapeutics, Inc. (0001861123) (Filer)

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)

Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005Presented data at the American Society for Clinical Oncology (ASCO) 2026 Annual Meeting demonstrating encouraging activity of EIK1001 combined with pembrolizumab and histology-appropriate chemotherapy for the front-line treatment of patients with advanced NSCLC in the TeLuRide-005 Phase 2 trial, and preliminary evidence that the PARP1-selective inhibitor EIK1003 could be safely combined with full-dose paclitaxel

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following a prespecified analysisDMC recommended that the TeLuRide-006 study continue as planned in all other respects MILLBRAE, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in

MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently serves as Vice President, and Head of Discovery Chemistry at Merck Research Laboratories. Eikon has a long-standing relationship with Merck (known as MSD outside of the US and Canada). Merck has provided their anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), for registration-enabling trials involving EIK1001, Eikon’s systemically administered TLR7/8 dua

SCHEDULE 13G/A - Eikon Therapeutics, Inc. (0001861123) (Subject)

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)

MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). "Treating the first patient in TeLuRide-008 is a significant milestone for Eikon as we continue to advance EIK1001 in multiple indications, with the ultimate goal of de

Presentations to cover updates across Eikon’s clinical pipeline including:  Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemotherapy in stage 4 non-small cell lung cancer (NSCLC)Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumorsInitial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancerInitial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index following the annual reconstitution, effective after the US market closes on June 26, 2026. The Russell US Indexes, from mega cap to microcap, serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current and historical market performance by specific market segment or investment style (growth/value/defensive/dynamic). The

3 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the appointment of Ma. Fatima ("Fama") D. Francisco as an independent director to Eikon's Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board. "Fama brings a remarkable record of leadership, innovation and talent development from one of the world's most successful global enterprises," said Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer of Eikon. "Her per

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease control, strengthening the case for continued developmentPhase 1/2 trial of EIK1003 reports updated safety and efficacy monotherapy data and initial combination data with weekly paclitaxel in patients with advanced solid tumors MILLBRAE, Calif., May 30, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced presentations on several

Presentations to cover progress across Eikon's most advanced clinical-stage programsUpdated data will include those derived from trials of EIK1001, for the treatment of patients with non-small cell lung cancer ("NSCLC"), EIK1003, as a monotherapy or in combination in the treatment of patients with breast, ovarian, prostate, or pancreatic cancer, and EIK1005, which is designed to improve treatment of patients whose tumors demonstrate certain DNA replication abnormalities. MILLBRAE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet me

SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

10-Q - Eikon Therapeutics, Inc. (0001861123) (Filer)

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)

Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitorSix abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company's lead programs including new safety, tolerability, and efficacy data Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking (SMT) to advance

SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

8-K - Eikon Therapeutics, Inc. (0001861123) (Filer)